Pharmaceutical

Risk adjusted net present value: What is the current valuation of IN8bio’s INB-400?

INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).

Dec 15, 2024 - 06:00
INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Vigil Neurosci...

Next Article

Risk adjusted net present value: What is the current valuation of Cullinan Thera...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: No parent who has seen the children I’ve treated for measles would refuse a vaccine

Opinion: No parent who has seen the children I’ve treat...

Mar 13, 2024

STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more

STAT+: Pharmalittle: We’re reading about a U.S. vaccine...

Feb 9, 2024

STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts

STAT+: $100 billion estimate for Ozempic-style weight l...

Dec 5, 2023